Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study

PURPOSE: We conducted a first-in-human, dose-escalation study, to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and activity of TAK-931, a cell division cycle 7 inhibitor, in Japanese patients with advanced solid tumors. EXPERIMENTAL DESIGN: Patients ages ≥20 years received...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuboki, Yasutoshi, Shimizu, Toshio, Yonemori, Kan, Kojima, Takashi, Kondo, Shunsuke, Koganemaru, Shigehiro, Iwasa, Satoru, Harano, Kenichi, Koyama, Takafumi, Lu, Vickie, Zhou, Xiaofei, Niu, Huifeng, Yanai, Tomoko, Garcia-Ribas, Ignacio, Doi, Toshihiko, Yamamoto, Noboru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035389/
https://www.ncbi.nlm.nih.gov/pubmed/36970056
http://dx.doi.org/10.1158/2767-9764.CRC-22-0277

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035389/
https://www.ncbi.nlm.nih.gov/pubmed/36970056
http://dx.doi.org/10.1158/2767-9764.CRC-22-0277

Ejemplares similares